[Targeted degradation of epidermal growth factor receptor in nasopharyngeal carcinoma by chimeric molecule]

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy.
• Targeted protein degradation offers a novel therapeutic strategy.
• Nasopharyngeal carcinoma (NPC) remains a significant health challenge.

Purpose of the Study:

• To investigate the efficacy of EGF-PROTAC in targeting EGFR degradation.
• To evaluate the impact of EGF-PROTAC on CNE-2 cell proliferation and apoptosis.
• To explore the potential of EGF-PROTAC as a therapeutic agent for nasopharyngeal carcinoma.

Main Methods:

• Utilized chimeric EGF-PROTAC molecules for targeted EGFR degradation.
• Employed in vitro assays including Western blot, CKK-8, flow cytometry, and Transwell migration.
• Assessed biological effects on human nasopharyngeal carcinoma CNE-2 cells.

Main Results:

• EGF-PROTAC significantly reduced EGFR protein expression in CNE-2 cells.
• Demonstrated a marked decrease in CNE-2 cell survival rates.
• Observed a significant increase in CNE-2 cell apoptosis.
• Showcased a significant reduction in CNE-2 cell invasion capabilities.

Conclusions:

• EGF-PROTAC effectively targets and degrades EGFR via the ubiquitin-proteasome pathway.
• EGF-PROTAC demonstrates potent inhibition of CNE-2 cell proliferation and invasion.
• EGF-PROTAC promotes apoptosis in nasopharyngeal carcinoma cells in vitro.